TrademarkDir
CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT
DEAD

Serial Number

86434375

Owner

NEUROVANCE, INC.

Attorney

Michael P. Straher

Filing Date

Sep 19, 2014

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT Trademark

Serial Number: 86434375

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT is a trademark filed by NEUROVANCE, INC. on September 19, 2014. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NEUROVANCE, INC. (4 trademarks)

43 Thorndike Street, Suite S1-3
Cambridge, MA 02141

Entity Type: 03

Trademark Details

Filing Date

September 19, 2014

Registration Date

Not Registered

Published for Opposition

April 7, 2015

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jul 9, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 9, 2018 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 8, 2017 EXRA
SOU EXTENSION 5 GRANTED
Dec 7, 2017 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 7, 2017 AITU
SOU EXTENSION 5 FILED
Dec 1, 2017 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 1, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 6, 2017 EXRA
SOU EXTENSION 4 GRANTED
Jun 2, 2017 EX4G
SOU EXTENSION 4 FILED
Jun 2, 2017 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 2, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2016 EXRA
SOU EXTENSION 3 GRANTED
Dec 19, 2016 EX3G
SOU EXTENSION 3 FILED
Dec 2, 2016 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 2, 2016 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 9, 2016 EXRA
SOU EXTENSION 2 GRANTED
Jul 8, 2016 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 5, 2016 AITU
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 27, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 27, 2016 REAP
SOU EXTENSION 2 FILED
Jun 2, 2016 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 2, 2016 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 2, 2016 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 4, 2015 EXRA
SOU EXTENSION 1 GRANTED
Dec 2, 2015 EX1G
SOU EXTENSION 1 FILED
Dec 2, 2015 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 2, 2015 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 2, 2015 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 7, 2015 NPUB
PUBLISHED FOR OPPOSITION
Apr 7, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 18, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 3, 2015 PREV
ASSIGNED TO LIE
Mar 3, 2015 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 11, 2015 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 11, 2015 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 11, 2015 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 11, 2015 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 11, 2015 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 6, 2015 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jan 27, 2015 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2015 CNSA
ASSIGNED TO EXAMINER
Jan 5, 2015 DOCK
REQUEST TO CORRECT FILING DATE - GRANTED
Nov 17, 2014 CFDG
ASSIGNED TO PETITION STAFF
Nov 17, 2014 APET
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 4, 2014 NWOS
NEW APPLICATION ENTERED
Oct 28, 2014 NWAP
REQUEST TO CORRECT FILING DATE RECEIVED
Oct 24, 2014 RCFR
FAX RECEIVED
Oct 24, 2014 FAXX

Related Trademarks

More from this Owner

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

NEUROVANCE

NEUROVANCE

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT